HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING VIDEO EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options            My Account    Help    
Quote:
Login Free Membership
Search:

RELATED LINKS
Free Membership
Premium Home
Zacks #1 Rank
Real Time Insight
Equity Research
My Portfolio
Stock Screener
Premium Screens
Mutual Funds
ETFs
RSS Feed
Profit from the Pros
Subscription Services
FTM Trader
Product Guide
Zacks Premium
Method for Trading
Chart Patterns Trader
Home Run Investor
Income Plus
Insider Trader
Options Trader
Reitmeister Trader
Reitmeister Value
Tactical Trader
Top 10 Stocks
Turnaround Trader
Whisper Trader
Research Wizard
Zacks Ultimate



Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive


BVF: CME SNOWFL MIA JAN - Stock Quote Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Quote |  Detailed Quotes |  Real Time |  Options Chain |  Greeks Montage

CME SNOWFL MIA JAN (CMESP_INDEX)
BVF 12.00 N/A (N/A%) Vol.  0 13:58 ET

Zacks Rank: N/A - Not Rated

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
# 1Strong Buy26.04%
# 2Buy18.27%
# 3Hold9.49%
# 4Sell3.94%
# 5Strong Sell1.6%
S&P5009.23%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


Day Low - High N/A - N/A
52wk Low - High 12.00 - 12.00
Avg Volume 2,708,855
Industry MED-DRUGS
Market Cap 14.73 B
Div - Yield 0.00 - 0.00
PE (forward) 10.92
PEG Ratio .56
Current Year Est. 4.4
EPS Last Year 3.34
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
# 1Strong Buy26.04%
# 2Buy18.27%
# 3Hold9.49%
# 4Sell3.94%
# 5Strong Sell1.6%
S&P5009.23%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


Short-Term Rating 1-3 Months
Zacks #1 Rank Strong Buys Zacks Premium
N/A
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
All Outperform Rated Stocks Zacks Premium
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 05/18/2012
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
CME SNOWFL MIA JAN BVF N/A
GRIFOLS SA-ADR GRFS 1
NATURES SUN PRD NATR 1
VALEANT PHARMA VRX 1
Top Peer Analysis Zacks Premium
See all MED-DRUGS Peers

BROKERAGE RECOMMENDATIONS
Current ABR 1.56
ABR (Last Week) 1.56
# of Recs in ABR 18
Average Target Price 62.26
Rank in Industry 54 out of 97
More Brokerage Recommendations


NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 NEW!   Fundamental Charts




Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate BVF?

Buy Sell
Find out what the Zacks Community
thinks of BVF at PeopleAndPicks.com
 
ZACKS COMMENTARY FOR BVF
Zacks Equity Research: Report for BVF
May 18, 2012
:
More Zacks Commentary
NEWS
Cortex Reports First Quarter Operating Results
May 15, 2012
Cortex Reports First Quarter Operating Results - Story Title - Comtex
May 15, 2012
Biovail Corp. Reports Operating Results (10-Q) - GuruFocus
May 04, 2012
Valeant Pharmaceuticals International acquires Pedinol Pharmacal
Apr 13, 2012
Valeant Pharmaceuticals International acquires Pedinol Pharmacal - Story Title - Comtex
Apr 13, 2012
Myriant Appoints William M. Wells and Dhanes Charoensupaya, Ph.D. to Its Board of Directors
Mar 26, 2012
Myriant Appoints William M. Wells and Dhanes Charoensupaya, Ph.D. to Its Board of Directors - Story Title - Comtex
Mar 26, 2012
Biovail Corp. Reports Operating Results (10-K) - GuruFocus
Feb 29, 2012
More News
EARNINGS ESTIMATES
  This Quarter
N/A
Next Quarter
N/A
This Year
N/A
Next Year
N/A
Average Estimate N/A N/A N/A N/A
Number of Estimates N/A N/A N/A N/A
Low Estimates N/A N/A N/A N/A
High Estimate N/A N/A N/A N/A
Year Ago EPS N/A N/A N/A N/A
EPS Growth N/A% N/A% N/A% N/A%

More Estimates

COMPANY DESCRIPTION
Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant's development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.

Full Company Report
FINANCIALS
EPS TTM 3.34
Sales 2463.45
Net Income 140.16
Price/Earnings 14.38
Price/Book 3.61
Price/Cash Flow 9.78
Price/Sales 5.41


More Financials

 
About Zacks | Advertise | Affiliate | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2012 Zacks Investment Research